Verona Pharma plc (NASDAQ:VRNA) shares rose 2.5% post-annual results release, exceeding revenue expectations by 8.9%. Analysts predict a 629% revenue increase in 2025, with earnings improving. Price target raised to US$81.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay